

Report of the Topical Calcineurin Inhibitor Task Force of the ACAAI and AAAAI

This task force report was reviewed on Feb 1, 2006 and the committee decided that no update was needed at that time

Luz Fonacier (ACAAI Co-Chair), Jonathan Spergel, Ernest N. Charlesworth, David Weldon, Vincent Beltrani, Jan Bernhisel-Broadbent, Mark Boguniewicz, Donald Y. M. Leung (AAAAI Co-Chair)

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that causes significant suffering and has limited treatment options^{1,2}. It is often the first step in the atopic march and may contribute to the severity/persistence of asthma²⁻⁴. On February 15, 2005, the Pediatric Advisory Committee of the Food & Drug Administration (FDA) recommended "black box" warnings for pimecrolimus (Elidel, Novartis) and tacrolimus (Protopic, Fujisawa) because of a potential risk of cancer. The ACAAI and the AAAAI formed a Joint Task Force to review the data and present it to their membership with the following objectives:

- 1. To review current FDA concerns regarding safety of the use of topical pimecrolimus (Elidel®, Novartis) and tacrolimus (Protopic®, Fujisawa) in atopic dermatitis (AD).**
- 2. To assist the allergist in providing their patients with appropriate information and to assist them in proper use of these products**
- 3. To address the Black Box Warning and its impact on the treatment of AD at this time**

I. FDA Concerns:

A. Because of a perception by physicians and patients that topical pimecrolimus and tacrolimus are safer than steroid preparations, they have increasingly been used as first-line therapy and off label. There were almost 2 million prescriptions written of these topical medications for children between June 2003 and May 2004 and approximately half a million were for those under 2 years of age. There is also heavy direct-to-consumer advertising, which may be related to its increasing use.

B. The FDA is investigating post-marketing reports of malignancy in children and adults who have used these medications (Table 1 & 2). A post marketing non-human primate study with an oral formulation of pimecrolimus demonstrated an occurrence of lymphoma in monkeys

exposed to the lowest dose, which represented 30x the maximum recommended human dose (MRHD)⁵.

C. A definitive answer regarding risk of carcinogenicity from topical pimecrolimus and tacrolimus will not be known for years, and if such a risk was real, the Advisory Panel was concerned that people may think they were not provided adequate information to assist them in proper use of these products.

II. Current Data:

A. After topical application of tacrolimus and pimecrolimus, serum concentrations are usually low or undetectable⁵⁻⁸, and absorption decreases as dermatitis improves. Additional absorption studies are needed in infants and young children.

B. Although there are animal data showing dose dependent carcinogenicity, it should be noted that the lymphoma formation was only reported in mice with the application of tacrolimus and pimecrolimus dissolved in ethanol at 26X and 47X the maximum recommended human dose (MRHD)⁵.

C. Based on the malignancy rates in the general population of the United States for tacrolimus (Table 3) and the incidence of Non Hodgkin's Lymphoma based on the person-years of exposure for pimecrolimus (Table 4), there is no evidence of increased incidence of lymphoma with the short-term or intermittent long-term application of topical tacrolimus and pimecrolimus at this time, despite the use of these drugs in nearly 7 million people.

D. There are features that characterize lymphomas occurring in the setting of immunomodulatory or immunosuppressive therapy. These are: 1) frequent occurrence in unusual sites including soft tissue, joint spaces, lungs; 2) polymorphous, pleomorphic large cell or Hodgkin's-like morphology; 3. presence of Epstein Barr genome in lymphoma cells; 4) B-cell lymphomas develop weeks, months or less commonly up to several years of receiving immunomodulatory therapy; 5) In a significant percentage of cases (30-50%), the lymphomas spontaneously regress following withdrawal of immunomodulatory therapy without the need for chemotherapy or radiation therapy.

None of the information provided for the cases of lymphoma associated with the use of topical pimecrolimus or tacrolimus in AD indicate or suggest a causal relationship. The histology reported and the clinical presentations are not those usually associated with post transplant lymphoproliferative disorder or of lymphoma occurring in the

immunocompromised setting. Five independent external experts in the areas of dermatology, epidemiology, Posttransplantation Lymphoproliferative Disorders (PTLD)/oncology, and pediatric oncology concluded that there was no clear-cut link between pimecrolimus or tacrolimus⁵ and increased risk of lymphoma.

E. There is no evidence of systemic immunosuppression from topical pimecrolimus or tacrolimus as measured by response to childhood immunizations (B cell)^{9,10} and delayed hypersensitivity (T cell)^{11,12}.

F. In clinical trials, infants and children younger than 2 years of age treated with topical pimecrolimus were reported to have higher rates of upper respiratory infections than those treated with placebo cream. However, when data was adjusted for time on medication, pimecrolimus was not associated with increased prevalence of systemic infection. There was also no difference in systemic infections in children 2-17 years of age or adults^{5, 9, 12-16}.

G. AD itself has been associated with malignancy, such as cutaneous T cell lymphoma¹⁷.

H. There is an increased risk of adverse effects and malignancies among users of oral corticosteroids^{18,19} and other systemic therapies such as cyclosporin and psoralen plus ultraviolet A (PUVA) for AD that are occasionally required for treatment of severe AD.¹⁸⁻³² (Table 5)

III. Conclusions and Recommendations

A. Guidelines for the use of pimecrolimus cream 1% and tacrolimus ointment 0.03 and 0.1%.

1. Current FDA guidelines recommend that topical pimecrolimus and tacrolimus are indicated for the short term or intermittent long term treatment of AD in patients \geq 2 years who are unresponsive to or intolerant of other conventional therapies or in whom these therapies are inadvisable due to potential risks.
2. The long-term effect of pimecrolimus and tacrolimus on the developing immune system in infants and children is not known. Children and adults with a compromised immune system should not use pimecrolimus or tacrolimus.
3. Based on information available, it would be prudent to use these medications as has been previously recommended and approved and at the amount needed to control the patient's symptoms. Animal data suggest that the risk of cancer increases with increased exposure to pimecrolimus

- or tacrolimus. However the doses in which cancers occur were substantially higher than the levels used in humans.
4. It is important to reinforce the need for adjunctive treatment for AD including liberal moisturization, evaluation for food and inhalant allergies, treatment of infections and referral to an allergist/immunologist or a dermatologist for identification of triggers and optimal skin care.
 5. There is no evidence to date of systemic immunosuppression after short-term or intermittent long-term topical application of FDA approved formulations of pimecrolimus and tacrolimus in patients with AD.

B. Patient information should be adequate and must include the risk and benefits of the drug and the proper use of these products. This includes:

1. Addressing the chronic, relapsing nature of AD and its complications such as infection, associated allergies, skin barrier dysfunction, risk of asthma etc.
2. Acknowledging that topical calcineurin inhibitors have significantly improved the clinical management of patients with AD.
3. Discussing current product label in the use of these drugs on patients
 - a. younger than 2 years of age
 - b. with compromised immune system
 - c. treated with concurrent phototherapy
 - d. pregnant or breast feeding
 - e. with severely impaired skin barrier function (e.g. Netherton's syndrome) that may result in immunosuppressive blood levels of the drug
4. Discussing treatment options for AD, including topical corticosteroids that may have adverse effects relating to potency, occlusiveness of the preparation, site of application, percentage of body surface covered, and duration of treatment including skin atrophy.
5. Discussing alternative treatments for moderate to severe AD, which include oral corticosteroids, cyclosporin A and phototherapy, all of which have significant potential for causing serious adverse events including malignancy.

C. The Topical Calcineurin Inhibitor Task Force of ACAAI and the AAAAI concludes that based on current data, the risk-benefit ratio of topical pimecrolimus and tacrolimus are similar to most conventional therapies for the treatment of chronic relapsing eczema.

In children < 2 years of age with poorly controlled persistent AD who require more than hydration and use of emollients to keep their skin disease under control, use of off label therapy may be necessary as most topical steroids or other immunomodulators have not been studied or approved in this age group.

IV. Black Box Warning

Current data does not support the use of the black box warning on topical pimecrolimus and tacrolimus based on the following facts:

1. Lymphoma formation is generally associated with high dose and sustained systemic exposure to pimecrolimus and tacrolimus.
2. The reported cases of lymphoma from topical pimecrolimus and tacrolimus are not consistent with lymphomas observed with systemic immunomodulator therapy.
3. The actual rate of lymphoma formation reported to date for topical calcineurin inhibitors is lower than predicted in the general population.

Current labeling and product package inserts for both topical pimecrolimus and tacrolimus clearly state the potential of malignancy in animal studies. There is no new data except for a few cases of post marketing adverse events that are anecdotal at this time and a non-human primate study with an oral formulation of pimecrolimus demonstrating an occurrence of lymphoma in the lowest dose representing 30x MRHD.

V. Recommendation:

1. More controlled studies are needed on the use of topical calcineurin inhibitors, especially under the age of 2 years old
2. Controlled long term safety studies are also needed for topical corticosteroids in patients with AD, especially those under 2 years of age.
3. Likewise, warnings regarding the use of unproven treatments perceived to be safer than conventional therapies are warranted.
4. Vigilance and education on the prudent use of all products for management of AD are needed.

Tables of Post marketing Data: (after 12/08/00 for Topical Tacrolimus & 12/13/01 for Topical Pimecrolimus)

Table 1: Post Marketing Total Tumor Adverse Events as of December 31, 2004.

		Total Tumor⁵	Total US cases of Lymphoma⁵	**Median time from initial treatment until diagnosis⁵
Pimecrolimus	Children \leq 16 yrs	1	1	90 (7 to 300 days)
	Adult	5†	3†	
Tacrolimus	Children \leq 16 yrs	3	0	240 (21 to 940 days)
	Adult	18	4	

† There is one non-US case of lymphoma that is poorly documented.

Table 2: US FDA cases of Spontaneous Reports of Lymphoma†⁵

Drug	Age	Lymphoma Histology	Independent Expert Assessment of Causality
Pimecrolimus	61	Histiocytic Lymphoma	Unlikely
Pimecrolimus	53	Subcutaneous panniculitis like T-cell lymphoma	Unlikely
Pimecrolimus	2.5	Lymphoblastic lymphoma (T cell)	Unlikely
Tacrolimus	52	Non-Hodgkin's Lymphoma	Insufficient evidence
Tacrolimus	50	Anaplastic large cell lymphoma-T-cell "type"	Insufficient evidence
Tacrolimus	40	Lymphoma "possible"	Insufficient evidence
Tacrolimus	54	Non-Hodgkin's Lymphoma	Insufficient evidence

Table 3: Tacrolimus Analysis of Malignancy Rates

	Malignancy Rates in the General US Population	Malignancies Reported in Tacrolimus Treated patients[†]
Lymphoma	22/100,000^{34*}	0.65/100,000⁵
Non Melanoma Skin Cancer	533/100,000^{35**}	0.94/100,000⁵

***Surveillance Epidemiology & End Result (SEER) ** PHS**

[†] For the time period upto Dec 2004, 1,700,000 patients have been treated with tacrolimus. 11 lymphomas including 6 cutaneous T-cell lymphoma [CTCL] and 16 non-melanoma skin cancer have been reported in US⁵

Table 4: Pimecrolimus Analysis of Malignancy Rates⁵:

Based on the person-years of exposure, there is no evidence of increased incidence of Non Hodgkin's Lymphoma in any age group in patients receiving pimecrolimus

	<5	5-9	10-14	15-19	Total Children	Total adults	Total (US)
Person yrs of exposure	278,842	118,196	65,224	33,431	495,694	237,030	732,724
Expected no of cases (SEER)^{35*}	1.8	1.0	0.7	0.5	4.0	42.1	46.1
Reported Cases⁵	1	0	0	0	1	2	3

*** Surveillance Epidemiology & End Result**

Table 5: Malignancy Risks of Anti-Inflammatory Therapy used in Atopic Dermatitis

Therapy	Malignancy Risk	Adverse Event
Topical Corticosteroids*	Evidence-based: No evidence of immunosuppressive malignancy	HPA axis suppression; skin atrophy; telangiectasia; percutaneous absorption; ↓ bone mineral density ^{31, 37-44}
Oral Corticosteroids**	Increase risk of squamous cell/basal cell carcinoma; increase risk of non-Hodgkin's lymphoma ^{18,19}	↑ infection, hypertension, myopathy, glaucoma, aseptic necrosis of the hip, cataracts, Cushing Syndrome, cataracts, weight gain, osteopenia ^{45,46}
Topical Calcineurin Inhibitors	Theoretical: topical dosing can induce cancer in mice at >40x maximum human recommended dose ^{6,7} Evidenced-based: No evidence of immunosuppressive malignancy	Skin irritation at application site ^{6,7,11,45-49}
Oral Immunosuppressives (cyclosporin A)**	Increases B cell Lymphoproliferative Disease and skin cancer. No significant risk if therapy less than 2 year ^{21,26,29,30}	Nephrotoxicity; hepatotoxicity ^{24,46,52,53}
Phototherapy (UVA, UVB) Photochemotherapy (PUVA)	Increased risk of squamous cell and basal cell carcinoma, & malignant melanoma ^{20,23,27,28,33} (UVB less than PUVA) ²²	Erythema, pruritis, nausea, headache, chronic actinic skin damage, dyskeratotic and precancerous skin conditions ^{20,23,25,32}

* adverse effects relate to corticosteroid potency, occlusiveness of the preparations, site of application, percentage of the body surface covered, and duration of treatment

** occasionally required for severe atopic dermatitis treatment

References:

1. Leung DYM, Bieber T. Atopic dermatitis. *Lancet* 2003; 361(9352):151-60.
2. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. *J Allergy Clin Immunol* 2003; 112:S118-27
3. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. *J Allergy Clin Immunol* 2004; 113:101-8.
4. Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004; 113:925-31.
5. Novartis and Fujisawa FDA Briefing Statements. Pediatric Advisory Committee Meeting of the US Food Drug Administration. Washington, DC, 2005. <<http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm>>
6. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. *Br J Dermatol* 2001;144:781-7.
7. Protopic (Tacrolimus) Ointment New Drug Application 50-777 Approval Date 12/8/2000. <http://www.fda.gov/cder/foi/nda/2000/50777_protopic.htm>
8. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. *Dermatology* 2002; 204:63-8.
9. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. *J Am Acad Dermatol* 2005; 52:247-53.
10. Stiehm E, Roberts R, Kaplan M, Corren J, Jaracz E, Rico M. Pneumococcal seroconversion after vaccination in children with atopic dermatitis treated with tacrolimus ointment. *Proceedings of the American Academy of Dermatology 61th annual meeting; 2003 March 21-26; San Francisco, CA. J Am Acad Dermatol* 2005 2003:in press.
11. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. *Arch Dermatol* 2000; 136:999-1006.
12. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics* 2002; 110:e2.

13. Papp KA, Werfel T, Folster-Holst R, Ortonne JP, Potter PC, de Prost Y, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. *J Am Acad Dermatol* 2005; 52:240-6.
14. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *J Pediatr* 2003; 142:155-62.
15. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. *J Am Acad Dermatol* 2001; 44:S58-64.
16. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. *J Allergy Clin Immunol* 2002; 110:277-84.
17. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. *Cancer Causes Control* 2004; 15:419-28.
18. Karagas MR, Cushing GL, Jr., Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. *Br J Cancer* 2001; 85:683-6.
19. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. *J Natl Cancer Inst* 2004; 96:709-11.
20. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. *Cancer* 1994; 73:2759-64.
21. Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. *J Am Acad Dermatol* 2002; 47:S165-7.
22. Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet a-treated patients. *J Invest Dermatol* 2005; 124:505-13.
23. Momtaz K, Fitzpatrick TB. The benefits and risks of long-term PUVA photochemotherapy. *Dermatol Clin* 1998; 16:227-34.
24. Zonneveld IM, De Rie MA, Beljaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. *Br J Dermatol* 1996; 135 Suppl 48:15-20.
25. van Praag MC, Tseng LN, Mommaas AM, Boom BW, Vermeer BJ. Minimising the risks of PUVA treatment. *Drug Saf* 1993; 8:340-9.
26. Sinha A, Velangi S, Natarajan S. Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A. *Acta Derm Venereol* 2004; 84:327-8.

27. Chuang TY, Heinrich LA, Schultz MD, Reizner GT, Kumm RC, Cripps DJ. PUVA and skin cancer. A historical cohort study on 492 patients. *J Am Acad Dermatol* 1992; 26:173-7.
28. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. *J Am Acad Dermatol* 2001; 44:755-61.
29. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. *Lancet* 1998; 351: 623-8.
30. Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. *J Lab Clin Med.* 2001; 137(1):14-20.
31. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. *J Am Acad Dermatol* 2001; 45:487-98; quiz 99-502.
32. Sheehan MP, Atherton DJ, Norris P, Hawk J. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. *Br J Dermatol* 1993; 129:431-6.
33. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. *N Engl J Med* 1997; 336:1041-5.
34. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds). *SEER Cancer Statistics Review, 1975-2001*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2001/, 2004.
35. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. *J Am Acad Dermatol.* 1994 May;30(5 Pt 1):774-8.
36. National Cancer Institute Probability of Developing Non-Hodgkin Lymphoma <http://seer.cancer.gov/faststats/html/dev_nhl.html
37. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH. Different skin thinning potential of equipotent medium-strength glucocorticoids. *Skin Pharmacol Appl Skin Physiol* 2002; 15:85-91.
38. Serup J, Holm P. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. *Dermatologica* 1985; 170:189-94.
39. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. *Pediatrics* 2000; 105:794-9.
40. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. *Br J Dermatol* 1986; 115:475-84.
41. Lucky AW, Grote GD, Williams JL, Tuley MR, Czernielewski JM, Dolak TM, et al. Effect of desonide ointment, 0.05%, on the

- hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. *Cutis* 1997; 59:151-3.
42. Matsuda K, Katsunuma T, Iikura Y, Kato H, Saito H, Akasawa A. Adrenocortical function in patients with severe atopic dermatitis. *Ann Allergy Asthma Immunol* 2000; 85:35-9.
 43. Denise Cook, MD, US Food Drug and Administration, Nonprescription Drugs Advisory Committee and the Dermatologic and Ophthalmic Drug Advisory Committee, March 24, 2005.
<http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4099S1_03_FDA-Cook_files/frame.htm#slide0173.htm>
 44. Aalto-Korte K, Turpeinen M. Bone mineral density in patients with atopic dermatitis. *Br J Dermatol* 1997; 136:172-5.
 45. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. *J Allergy Clin Immunol*. 2000 Oct;106(4):651-9.
 46. Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. *Clin Dermatol* 2003; 21:225-40.
 47. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkkö P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. *J Invest Dermatol* 1998; 111:396-8.
 48. Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. *Br J Dermatol* 2002; 146:342; author reply 3.
 49. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. *J Allergy Clin Immunol* 2003;112:S140-150.
 50. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. *Br J Dermatol* 2001; 144:507-13.
 51. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. *Br J Dermatol* 2004; 150:1174-81.
 52. Vitko S, Viklicky O. Cyclosporine renal dysfunction. *Transplant Proc*. 2004; 36(2 Suppl):243S-247S.
 53. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. *Clin Exp Dermatol* 2000; 25:559-66.

Declared Conflicts of Interest

Vincent Beltrani: Advisory Board: Pfizer; Speaker: Pfizer, Aventis, Fujisawa and AstraZeneca

Mark Boguniewicz: Research grants and Speaker's Bureau: Fujisawa and Novartis Pharmaceuticals

Jan Broadbent: Speaker's Bureau: Novartis

Ernie Charlesworth: Clinical Investigator: Novartis; Lecturer: Novartis and Fujisawa

Luz Fonacier: Speakers' Bureau: Novartis, Genetech, Aventis, Pfizer, GlaxoSKB; Research/Clinical trials: Genentech, Dyaxx, GlaxoSKB

Donald Leung: Speaker's Bureau, Consultant: Fujisawa, Novartis Pharmaceuticals, GlaxoSKB, Leo Pharmaceuticals, sanofi-aventis

Jonathan Spergel: Speaker's Bureau: GlaxoSKB, Fujisawa
Research/Clinical trials: Novartis

David Weldon: Speaker's Bureau: Primary Care Network, Aventis and GlaxoSmithKline; Consultant: AstraZeneca